Betrixaban

• Description:

  Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect[1][3].

• Product Name Alternative:

  PRT054021

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H373

• Target:

  Factor Xa

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Betrixaban.html

• Purity:

  98.02

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  N=C(N(C)C)C(C=C1)=CC=C1C(NC2=CC=C(OC)C=C2C(NC(C=C3)=NC=C3Cl)=O)=O

• Molecular Formula:

  C23H22ClN5O3

• Molecular Weight:

  451.91

• Precautions:

  H302, H373

• References & Citations:

  [1]Zhang P, et al. Discovery of Betrixaban (PRT054021), N- (5-chloropyridin-2-yl) -2- (4- (N, N-dimethylcarbamimidoyl) benzamido) -5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19 (8) :21|[2]Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 Apr;19 (4) :446-51.|[3]Chan NC, et al. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  330942-05-7